Joan Mendivil | Vice President, Global Evidence & Outcomes Research
Pharvaris

Joan Mendivil is Vice President of Global Evidence & Outcomes Research at Pharvaris, where he leads global strategies for evidence generation across the development lifecycle of deucrictibant in bradykinin‑mediated diseases. With deep expertise in health economics, outcomes research, and patient‑centered evidence generation, he is recognized for advancing robust and innovative approaches to demonstrate the value of orphan drugs. Throughout his career, Joan has been committed to improving patient outcomes and enabling informed healthcare decision‑making through high‑quality clinical, patient experience, and real‑world evidence. His work focuses on designing fit‑for‑purpose evidence strategies that balance scientific rigor with regulatory and payer expectations in rare diseases. At Pharvaris, Joan has played a key role in the validation of novel clinical and patient‑reported endpoints, as well as in the generation of real‑world evidence supporting the development of deucrictibant for hereditary angioedema. He is known for his strategic perspective, collaborative leadership, and strong commitment to patient‑centric drug development. As a speaker at the World Orphan Drug Congress USA 2026, Joan will share insights on emerging trends, challenges, and best practices in evidence generation for orphan drugs, drawing on his experience at the intersection of clinical development, real‑world evidence, and patient‑focused outcomes research.